RxDoctor Payments Data

Maggie Bistodeau, PA

Physician Assistant · Tea, SDNPI 1407524622

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 84 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$232
  • AbbVie$218
  • AstraZeneca$163
  • Pfizer$139
  • Novo Nordisk$137
  • Amgen$111
  • plus $487 from 14 others

What the payments were for

  • Food & beverage$1,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,486 in reported general payments places this provider in the 80th percentile of 548 physician assistant providers in South Dakota.

See all physician assistant providers in South Dakota

Medicare billing

Part B allowed, 2024
$23,095
Medicare patients
115
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin18$22,389
Spiriva RespimatTiotropium Bromide11$10,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,978
Breo ElliptaFluticasone/Vilanterol11$4,338
Potassium Chloride36$1,002
Atorvastatin Calcium83$734
Omeprazole91$713
Albuterol Sulfate HfaAlbuterol Sulfate26$587
Metoprolol Succinate28$543
Levothyroxine Sodium70$514
Losartan Potassium61$490
Rosuvastatin Calcium69$488
ValacyclovirValacyclovir Hcl19$469
Amlodipine Besylate83$467
Ezetimibe15$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$41$33,12629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 548 physician assistant providers in South Dakota.

Other physician assistant in Tea

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →